559 related articles for article (PubMed ID: 8706040)
1. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
2. In vivo studies of the new gonadotropin-releasing hormone antagonist--copolymer conjugates having antitumor activity.
Vincze B; Pályi I; Gaál D; Pató J; Móra M; Mezõ I; Teplán I; Seprõdi J
Cancer Detect Prev; 1996; 20(2):153-9. PubMed ID: 8706041
[TBL] [Abstract][Full Text] [Related]
3. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
4. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
5. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide).
Kakar SS
Cancer Res; 1998 Oct; 58(20):4558-60. PubMed ID: 9788600
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate.
Mezö G; Mezö I; Pimm MV; Kajtár J; Seprödi J; Teplán I; Kovács M; Vincze B; Pályi I; Idei M; Szekerke M; Hudecz F
Bioconjug Chem; 1996; 7(6):642-50. PubMed ID: 8950483
[TBL] [Abstract][Full Text] [Related]
8. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
Fister S; Günthert AR; Emons G; Gründker C
Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
[TBL] [Abstract][Full Text] [Related]
10. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
11. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
[TBL] [Abstract][Full Text] [Related]
12. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma.
Castellón E; Clementi M; Hitschfeld C; Sánchez C; Benítez D; Sáenz L; Contreras H; Huidobro C
Cancer Invest; 2006; 24(3):261-8. PubMed ID: 16809153
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.
Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF
J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910
[TBL] [Abstract][Full Text] [Related]
14. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
Gründker C; Völker P; Schulz KD; Emons G
Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
Borri P; Coronnello M; Noci I; Pesciullesi A; Peri A; Caligiani R; Maggi M; Torricelli F; Scarselli G; Chieffi O; Mazzei T; Mini E
Gynecol Oncol; 1998 Dec; 71(3):396-403. PubMed ID: 9887238
[TBL] [Abstract][Full Text] [Related]
16. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
17. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
[TBL] [Abstract][Full Text] [Related]
19. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP.
Ravenna L; Salvatori L; Morrone S; Lubrano C; Cardillo MR; Sciarra F; Frati L; Di Silverio F; Petrangeli E
J Androl; 2000; 21(4):549-57. PubMed ID: 10901441
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]